Low Dose Naltrexone Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a chronic inflammatory disorder that affects the joints, causing pain, swelling, and stiffness. In the quest for effective treatments, researchers and patients alike have explored various options, including medications like low dose naltrexone (LDN). In this article, we will talk about the potential benefits, considerations, and current understanding of using low dose naltrexone for rheumatoid arthritis.

What is Rheumatoid Arthritis?

Rheumatoid arthritis is an autoimmune condition where the immune system mistakenly attacks the joints, leading to inflammation and damage. This can result in persistent pain, joint deformities, and difficulty with daily activities. Conventional treatments often involve nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), and biologics to manage symptoms and slow down the progression of the disease.

What is Low Dose Naltrexone (LDN)?

Naltrexone is an FDA-approved medication typically used in higher doses to help individuals overcome opioid addiction. However, when used in much lower doses typically ranging from 1.5 to 4.5 milligrams, it has sparked interest in the medical community for it’s potential immunomodulatory effects.

The Mechanism of Action

While the exact mechanism is not fully understood, researchers believe that low dose naltrexone may work by modulating the immune system. It is thought to temporarily block opioid receptors, leading to increased production of endorphins which is the body’s natural painkillers. Additionally, LDN may influence immune cells and their activity, potentially reducing inflammation.

Research on LDN and Rheumatoid Arthritis

Research on the use of low dose naltrexone for rheumatoid arthritis is still in it’s early stages, and findings are mixed. Some studies and anecdotal reports suggest potential benefits, including reduced pain and improved function. However, the overall evidence is not yet robust enough to establish LDN as a mainstream treatment for RA.

Considerations and Caveats

  1. Consultation with Healthcare Professionals: Before considering LDN for rheumatoid arthritis, it is important to consult with healthcare professionals. They can provide personalized advice based on an individual’s specific health condition, medical history, and existing treatment plan.
  2. Individual Responses Vary: Responses to LDN can vary among individuals. What works for one person may not work for another. It is essential to approach LDN as a potential complementary therapy rather than a guaranteed solution.
  3. Balancing Risks and Benefits: As with any medication, there are potential side effects and risks associated with LDN. These can include insomnia, vivid dreams, and, in rare cases, liver function abnormalities. A thorough discussion with a healthcare provider can help weigh these potential risks against the perceived benefits.

Navigating the Decision to Try LDN:

  1. Patient Advocacy: Patients interested in exploring LDN for rheumatoid arthritis should advocate for themselves. Open communication with healthcare providers, sharing relevant research, and expressing concerns are vital steps in collaborative decision-making.
  2. Monitoring and Adjustments: If a decision is made to try LDN, close monitoring is essential. Regular follow-ups with healthcare providers can help track the impact on symptoms and make necessary adjustments to the treatment plan.


Low dose naltrexone’s potential role in managing rheumatoid arthritis is an intriguing avenue that continues to be explored. While some individuals report positive outcomes, the scientific community emphasizes the need for more rigorous research to establish it’s efficacy and safety definitively. As with any treatment decision, open communication with healthcare providers and a thorough understanding of the potential benefits and risks are important for informed choices in managing rheumatoid arthritis symptoms.

Leave a Reply

Your email address will not be published. Required fields are marked *